Trial Profile
A Phase I/II Study of Docetaxel/Prednisone and PTK 787/ZK 222584 [vatalanib] in Previously Untreated Metastatic Hormone Refractory Prostate Cancer.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Vatalanib (Primary) ; Docetaxel; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Oct 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 19 Aug 2008 New trial record.